This test detects somatic and germline SNV, InDel and CNV mutations in the BRCA1 and BRCA2 genes, covering the entire coding region of the BRCA1/2 gene and both flanking intron regions, provide information to guide PARP inhibitor therapy in breast & ovarian cancer.